# Erlotinib and Docetaxel in Second Line of Treatment in Patients With Non Small Cell Lung Cancer

> **NCT01350817** · PHASE2 · COMPLETED · sponsor: **University Hospital, Limoges** · enrollment: 156 (actual)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **DRUG:** Erlotinib + docetaxel
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT01350817
- **Lead sponsor:** University Hospital, Limoges
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-06
- **Primary completion:** 2013-03
- **Final completion:** 2014-01
- **Target enrollment:** 156 (ACTUAL)
- **Last updated:** 2026-05-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01350817

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01350817, "Erlotinib and Docetaxel in Second Line of Treatment in Patients With Non Small Cell Lung Cancer". Retrieved via AI Analytics 2026-09-03 from https://api.ai-analytics.org/clinical/NCT01350817. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*